Heart Health Boost: Top Foods and Habits for Vascular Protection

Link Between Diabetes Medication and Reduced Stroke Risk

• About 12.2 million new strokes occur each year.
• One in four stroke survivors will have another stroke.
• Stroke survivors face a higher risk of serious heart problems, like heart attack.

A recent study suggests that diabetes drugs—GLP-1 agonists and SGLT2 inhibitors—may lower the chances of a secondary stroke, heart attack, or death for stroke survivors who use them.

According to the World Stroke Association, one in four adults over 25 will have a stroke in their lifetime, and about 12.2 million strokes are diagnosed annually. Previous studies indicate that 25% of stroke survivors may experience another stroke. Moreover, those who have had a stroke are at a greater risk for heart-related issues soon after, such as myocardial infarction (heart attack).

For this study, researchers examined medical records of over 7,000 adults who had an ischemic stroke (the most common type, caused by a blood clot) from January 2000 to June 2022. They analyzed whether these patients were prescribed GLP-1 agonists or SGLT2 inhibitors post-stroke.

Dr. M. Ali Sheffeh, who led this research, explained that these diabetes medications help manage blood sugar and have additional benefits for the heart and kidneys. Such medications have shown better heart health outcomes in patients with obesity, diabetes, heart failure, and chronic kidney disease.

The study found that participants taking these medications had a lower risk of experiencing a secondary stroke compared to those who did not take them. Dr. Sheffeh noted that current guidelines recommend using blood thinners and controlling blood pressure as part of stroke prevention.

He suggested that validating their findings could lead to changes in treatment practices for stroke patients, potentially introducing these diabetes medications as preventive measures.

Dr. Sandra Narayanan, a vascular neurologist not involved in the study, remarked on the strong positive response these drugs had in reducing mortality, heart attack, or recurrent ischemic stroke. She highlighted compliance and education as significant barriers for patients.

Dr. Mir Ali, a general surgeon, found the study interesting. He acknowledged the potential benefits of GLP-1 and SGLT2 medications but noted the need for further research to understand their effects better, like whether the benefits stem from the drugs or from weight loss and improved glucose control.

This study opens the door to understanding how diabetes medications can support heart health, particularly for stroke survivors. Further research may confirm these findings and help improve treatment strategies.